Fundraising setback for Stemline as it puts off IPO
This article was originally published in Scrip
New York-based Stemline Therapeutics has decided now is not the right time to go to market, postponing its initial public offering in which it planned to raise up to $42 million by selling 3.5 million shares at $11 to $13 per share (scripintelligence.com, 23 July 2012).
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.